Zimmer Biomet Holdings, Inc. (NYSE:ZBH) – Equities researchers at Leerink Swann decreased their Q3 2017 earnings estimates for Zimmer Biomet Holdings in a report released on Thursday. Leerink Swann analyst R. Newitter now expects that the medical equipment provider will post earnings per share of $1.72 for the quarter, down from their previous forecast of $1.76. Leerink Swann has a “Outperform” rating and a $146.00 price objective on the stock. Leerink Swann also issued estimates for Zimmer Biomet Holdings’ FY2017 earnings at $8.21 EPS, FY2018 earnings at $8.63 EPS and FY2019 earnings at $9.54 EPS.

Zimmer Biomet Holdings (NYSE:ZBH) last released its quarterly earnings data on Thursday, July 27th. The medical equipment provider reported $2.08 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $2.10 by ($0.02). Zimmer Biomet Holdings had a net margin of 9.12% and a return on equity of 16.70%. The firm had revenue of $1.95 billion for the quarter, compared to the consensus estimate of $1.95 billion. During the same quarter in the prior year, the firm posted $2.02 earnings per share. The business’s revenue for the quarter was up 1.1% on a year-over-year basis.

TRADEMARK VIOLATION NOTICE: “Zimmer Biomet Holdings, Inc. (ZBH) to Post Q3 2017 Earnings of $1.72 Per Share, Leerink Swann Forecasts” was first posted by American Banking News and is the sole property of of American Banking News. If you are accessing this story on another domain, it was illegally copied and reposted in violation of United States & international copyright & trademark law. The legal version of this story can be accessed at https://www.americanbankingnews.com/2017/10/13/zimmer-biomet-holdings-inc-zbh-to-post-q3-2017-earnings-of-1-72-per-share-leerink-swann-forecasts.html.

A number of other brokerages have also weighed in on ZBH. Royal Bank Of Canada lifted their target price on shares of Zimmer Biomet Holdings from $133.00 to $140.00 and gave the stock an “outperform” rating in a research report on Wednesday, June 21st. Bank of America Corporation reaffirmed a “buy” rating and issued a $158.00 target price on shares of Zimmer Biomet Holdings in a research report on Friday, July 14th. BidaskClub downgraded shares of Zimmer Biomet Holdings from a “buy” rating to a “hold” rating in a research report on Monday, July 24th. Piper Jaffray Companies reaffirmed a “buy” rating and issued a $135.00 target price on shares of Zimmer Biomet Holdings in a research report on Friday, July 28th. Finally, Zacks Investment Research downgraded shares of Zimmer Biomet Holdings from a “hold” rating to a “sell” rating in a research report on Tuesday, August 1st. Three investment analysts have rated the stock with a sell rating, eight have issued a hold rating, thirteen have given a buy rating and one has issued a strong buy rating to the company. Zimmer Biomet Holdings has an average rating of “Hold” and a consensus target price of $136.55.

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, October 27th. Stockholders of record on Friday, September 22nd will be paid a dividend of $0.24 per share. The ex-dividend date is Thursday, September 21st. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.80%. Zimmer Biomet Holdings’s dividend payout ratio is presently 27.59%.

In other Zimmer Biomet Holdings news, VP Tony W. Collins sold 16,986 shares of the firm’s stock in a transaction on Monday, July 31st. The shares were sold at an average price of $121.74, for a total value of $2,067,875.64. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 1.07% of the company’s stock.

Large investors have recently added to or reduced their stakes in the company. Bronfman E.L. Rothschild L.P. grew its position in Zimmer Biomet Holdings by 25.3% during the second quarter. Bronfman E.L. Rothschild L.P. now owns 827 shares of the medical equipment provider’s stock valued at $106,000 after buying an additional 167 shares during the period. Parkside Financial Bank & Trust grew its position in Zimmer Biomet Holdings by 3.9% during the second quarter. Parkside Financial Bank & Trust now owns 872 shares of the medical equipment provider’s stock valued at $112,000 after buying an additional 33 shares during the period. BB&T Investment Services Inc. acquired a new stake in Zimmer Biomet Holdings during the second quarter valued at $144,000. Parallel Advisors LLC grew its position in Zimmer Biomet Holdings by 20.8% during the first quarter. Parallel Advisors LLC now owns 1,157 shares of the medical equipment provider’s stock valued at $138,000 after buying an additional 199 shares during the period. Finally, IHT Wealth Management LLC grew its position in Zimmer Biomet Holdings by 28.4% during the first quarter. IHT Wealth Management LLC now owns 1,158 shares of the medical equipment provider’s stock valued at $139,000 after buying an additional 256 shares during the period. Hedge funds and other institutional investors own 85.36% of the company’s stock.

Zimmer Biomet Holdings Company Profile

Zimmer Biomet Holdings, Inc is engaged in designing, manufacturing and marketing of orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; office-based technologies; spine, craniomaxillofacial and thoracic products; dental implants, and related surgical products.

Earnings History and Estimates for Zimmer Biomet Holdings (NYSE:ZBH)

Receive News & Ratings for Zimmer Biomet Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet Holdings Inc. and related companies with MarketBeat.com's FREE daily email newsletter.